Aptorum Group (Aptorum Group) Change In Inventory : $0.01 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Change In Inventory?

Aptorum Group's change in inventory for the quarter that ended in Jun. 2023 was $0.01 Mil. It means Aptorum Group's inventory declined by $0.01 Mil from Dec. 2022 to Jun. 2023 .

Aptorum Group's change in inventory for the fiscal year that ended in Dec. 2022 was $0.01 Mil. It means Aptorum Group's inventory declined by $0.01 Mil from Dec. 2021 to Dec. 2022 .

Aptorum Group's Total Inventories for the quarter that ended in Jun. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Aptorum Group's Days Inventory for the quarter that ended in Jun. 2023 was 6.00.

Inventory Turnover measures how fast the company turns over its inventory within a year. Aptorum Group's Inventory Turnover for the quarter that ended in Jun. 2023 was 30.43.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Aptorum Group's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.03.

Aptorum Group Change In Inventory Historical Data

The historical data trend for Aptorum Group's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Change In Inventory Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Inventory

Get a 7-Day Free Trial

-0.03

-0.01

0.01

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Inventory	Get a 7-Day Free Trial							0.01	-	0.01	-	0.01

Aptorum Group Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01 Mil.

Aptorum Group (NAS:APM) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Aptorum Group's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0.014	/	0.426	*	365 / 2
	=	6.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Aptorum Group's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.426	/	0.014
	=	30.43

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Aptorum Group's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0.014	/	0.431
	=	0.03

Aptorum Group Change In Inventory Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.